FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LARUE WILLIAM R						2. Issuer Name and Ticker or Trading Symbol CADENCE PHARMACEUTICALS INC CADX]								Relationship of Reportin (Check all applicable) Director Officer (give title below)			10% Oth	6 Owner er (specify	
(Last) (First) (Middle) C/O CADENCE PHARMACEUTICALS, IN 12481 HIGH BLUFF DRIVE, SUITE 200				NC.	3. Date of Earliest Transaction (Month/Day/Year) 11/21/2011										SVP, CFO, Treas, Asst Sec				
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - N	on-Deriv	ative	Seci	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefic	ially	Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day)						Execution Date,			3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			d 5) Secur Benet		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(Instr. 4)	
Common Stock 11/21/20					011	11			S ⁽¹⁾		10,000	D	\$4.16	532 ⁽²⁾		5,000	D		
Common Stock															1	1,000	I	By the LaRue Family Trust ⁽³⁾	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execut if any			ansaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Exerc tion Da h/Day/\		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			vative ırity	derivative Securities	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sahle	Expiration Date	Title	or Number of Shares						

Explanation of Responses:

- $1.\ The\ sale\ reported\ on\ this\ Form\ 4\ was\ effected\ pursuant\ to\ a\ Rule\ 10b5-1\ trading\ plan\ adopted\ by\ the\ reporting\ person\ on\ March\ 11,\ 2011.$
- 2. This transaction was executed in multiple trades at prices ranging from a low of \$4.0675 to a high of \$4.35. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. Mr. LaRue is a trustee of this trust.

Remarks:

/s/ Hazel M. Aker Attorney-in**fact**

11/22/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.